Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neridronic acid - Abiogen Pharma

Drug Profile

Neridronic acid - Abiogen Pharma

Alternative Names: AHBP; AHDP; AHHexBP; Aminohexane diphosphonate; Aminohexane-bisphosphonate; Attila; Neridronate; Neridronate-sodium; Nerixia

Latest Information Update: 21 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Istituto Gentili
  • Developer Abiogen Pharma; Austin Pain Associates; Grunenthal; Lee's Pharmaceutical; Shire Pharmaceuticals Group
  • Class Analgesics; Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Reflex sympathetic dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Osteitis deformans; Osteogenesis imperfecta
  • Registered Complex regional pain syndromes
  • Discontinued Malignant hypercalcaemia; Postmenopausal osteoporosis

Most Recent Events

  • 14 Aug 2019 Grunenthal terminates a phase III trial for Complex regional pain syndromes in USA (IV) (NCT03530345)
  • 01 Aug 2019 Grunrnthal terminates a phase III trial for Complex regional pain syndrome in USA, Canada, Czech Republic, Poland, Serbia, Slovakia and United Kingdom (NCT03560986) (EudraCT-2017-004244-37)
  • 31 May 2019 Grunrnthal initiates enrolment in a phase III trial for Complex regional pain syndrome in USA, Canada, Czech Republic, Poland, Serbia, Slovakia and United Kingdom (NCT03560986) (EudraCT-2017-004244-37)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top